Skip to main content
SpringerLink
Log in

Polypharmacy and comorbidities increase ADRs and costs

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. central nervous system

Reference

  • Liao P-J, et al. Factors associated with adverse drug reaction occurrence and prognosis, and their economic impacts in older inpatients in Taiwan: a nested case-control study BMJ Open : 13 May 2019. Available from: URL: http://dx.doi.org/10.1136/bmjopen-2018-026771

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Polypharmacy and comorbidities increase ADRs and costs. PharmacoEcon Outcomes News 828, 26 (2019). https://doi.org/10.1007/s40274-019-5900-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-019-5900-z

Search

Navigation